<a id='c5445b93-7ad0-4776-a682-734ecdd3f9a6'></a>

Parenteral Nutrition (PN) for the
Specialized Patient

<a id='07c670e2-bcb7-44f0-a7d9-c03e31725daf'></a>

NASPGHAN
FOUNDATION

<a id='4b2204be-f527-4cab-a59e-294c8f6df5e5'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" set against a blue gradient background, with a dark blue curved swoosh beneath it.::>

<a id='0cf33912-f243-46f3-9d1f-eae0c67553f7'></a>

# Outline

* Case
* Parenteral nutrition considerations in
    * Critical illness
    * Extracorporeal membrane oxygenation (ECMO)
    * Chylothorax
    * GI surgery, high ostomies
    * Liver disease
    * Renal disease
    * Inborn errors of metabolism
    * Short bowel syndrome/Intestinal Failure
* Case review

<a id='77f8487f-0f61-412d-9b4f-5d2130f35a83'></a>

<::NASPGHAN FOUNDATION logo
: figure::>

<a id='7108b4d8-974e-4da6-b97a-b5270f2d61a3'></a>

CAPTION ERROR

<a id='58725b32-7802-4410-9cec-1aad40a9a20a'></a>

<::logo: Case
Case
A blue rectangular background with white text.::>

<a id='1144eb85-898c-4d13-a907-c1426e743e3a'></a>

Lucy is a 5-month-old with biliary atresia and progressive end stage liver disease who is listed for transplant. She has been admitted on the GI ward for enteral nutrition to treat worsening malnutrition, however, is now transferred to PICU with fever, tachycardia, poor peripheral perfusion and hypoxia, requiring sedation and mechanical ventilation.

<a id='2ac39650-d4fb-4838-9be1-2c50e2a4e99a'></a>

1) What information would you like to assess her nutrition?
2) Would you recommend parenteral nutrition and when?
3) What factors would influence the energy requirements of this patient?

<a id='8bbae85f-7f60-4416-bfee-93228c77fd58'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='dd6c7785-4311-466e-aefe-efe3d887b25b'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line beneath the text.:>

<a id='00e719a6-987e-4f9a-9291-17a2502820d0'></a>

Pathophysiology of Injury in
Pediatric Intensive Care (PICU)

<a id='731f1dfb-da9d-409f-b934-62963d3e6811'></a>

<::A diagram illustrating the body's response to stress over time. 

On the left, a blue vertical bar indicates time-dependent phases:
- Top section: "Traditionally considered pre-resuscitative ebb phase and 'often' hypometabolic"
- Bottom section: "Traditionally considered flow phase and 'often' hypermetabolism"

A central vertical axis is labeled "Time" with markers for "Seconds", "Minutes", "Hours", "Days", and "Weeks".

On the right, a blue vertical bar indicates:
- Top section: "Central neuroendocrine response"
- Middle section: "Stressor" pointing to the brain, with examples listed as "Sepsis, burns, trauma, cardiac bypass, etc."
- Bottom section: "Recovery phase can last months with persistent hypermetabolism well past discharge from PICU"

In the center, an illustration of a human brain (cerebrum and cerebellum) is shown. Several colored lines originate from the brain, curving downwards and to the left, each representing a physiological response:
- Blue line: "Sympathetic nervous system", "Adrenergic receptors", "Adrenal medulla"
- Green line: "Hypothalamic-pituitary axis", "ACTH, TSH, GH, FSH, LH"
- Pink line: "Inflammation", "Immune system", "Cytokines, mediators"
- Orange line: "Behavioural"

Below these lines, central text reads: "Local tissue response > cell death (multi-organ failure) and/or subsequent recovery".
: diagram::>

<a id='ee0e9513-bfbe-4336-b3af-08ed5d18c290'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='aea9b598-3239-4e70-aa44-daa9ebc5e7ec'></a>

Preiser J-C, et al. Brit J Anaesth. 2014;113(5):945-54.

<a id='8199ab9d-8fea-4c95-912c-26530e75c5ac'></a>

CAPTION ERROR

<a id='73e18591-66c8-4260-8a9a-3ac4e3b1e9bc'></a>

Impact on Intermediary Metabolism

<a id='30edf5bc-3828-4fea-9914-bfae976b7b0c'></a>

CNS Hormones &
Catecholamines
* ↑gluconeogenesis
* ↑glycolysis
* ↑insulin resistance;
* ↑lipolysis & FFA release
* ↑proteolysis & hepatic synthesis acute phase proteins

Cytokines
* ↑proteolysis exceeds synthesis with ↑urinary nitrogen
* ↑lipolysis
* ↑insulin resistance
* ↑demand for and use of oxygen in tissues

<a id='01841ebd-d621-4071-8e68-70818d6742ea'></a>

<::diagram: A diagram illustrating the body's response to a stressor. An arrow labeled "Stressor" points to an illustration of a human brain. From the brain, four colored lines extend downwards, each associated with a physiological response:
- A blue line points to "Sympathetic nervous system", "Adrenergic receptors", and "Adrenal medulla".
- A green line points to "Hypothalamic-pituitary axis", and lists hormones: "ACTH, TSH, GH, FSH, LH".
- A pink line points to "Inflammation", "Immune system", and "Cytokines, mediators".
- An orange line points to "Behavioural".

All these responses "Together results in catabolism with resistance to anabolism causing:
• Skeletal muscle wasting
• Hyperglycemia
• High free fatty acids
• Hypertriglyceridemia
• High lactate levels"::>

<a id='8d81113d-1c75-4930-9208-742c59ec4e4c'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='e2484b92-2bae-456c-9726-7a8802429dbd'></a>

Preiser J-C, et al. Brit J Anaesth. 2014;113(5):945-54.

<a id='5cd726aa-bb78-424d-9ec2-d677ad37c5b9'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line underneath.::>

<a id='05acce2e-97dd-4ee7-b461-4d8c8b70dae9'></a>

Concepts of Inflammation and Immunosuppression in Critical Illness

<a id='f2f74e3c-0a38-4421-95d5-dad55169e633'></a>

- These patients are at high risk for severe malnutrition: another risk factor for secondary infections
- Going forward it will be important to understand if nutrition support in PICU might modify Systemic Inflammatory Response Syndrome (SIRS) and Compensatory Anti-inflammatory Response Syndrome (CARS)

<a id='1923eb02-5ba6-4156-b86b-712ab5a3fe1e'></a>

<::chart: A graph titled "Modified SIRS-CARS Model to Accommodate Multiple Hits" shows the Magnitude of Response on the y-axis over time (implied x-axis). The graph illustrates two scenarios: Uncomplicated recovery (solid lines) and Complicated recovery with 'second hit' (dashed-dotted lines).  

**SIRS (Systemic Inflammatory Response Syndrome)** is represented by red curves.  
- For uncomplicated recovery, a solid red curve peaks after an initial "trauma" and then gradually decreases.  
- For complicated recovery, a dashed-dotted red curve peaks after "trauma", decreases, and then peaks again after a "2nd hit".  

**CARS (Compensatory Anti-inflammatory Response Syndrome)** is represented by green curves.  
- For uncomplicated recovery, a solid green curve dips below the baseline and then returns towards the baseline.  
- For complicated recovery, a dashed-dotted green curve dips below the baseline, then dips further and remains suppressed after the "2nd hit".  

Below the graph, definitions are provided:  
- SIRS: Excessive Innate Immune Response  
- CARS: Suppressive Adaptive Immune Response::>

<a id='21158670-70c2-4667-a5d1-4e61fa580dde'></a>

<::NASPGHAN FOUNDATION logo
: figure::>

<a id='db8055e2-0e1d-4db9-85b9-d172a664b144'></a>

Preiser J-C, et al. Brit J Anaesth. 2014;113(5):945-54.

<a id='e069bddb-d8b6-4a85-9d71-ec7bd0b718ae'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, underlined by a dark blue curved swoosh.::>

<a id='e67e0bd0-2c60-4ba5-9175-493261beb925'></a>

# Malnutrition in Critical Illness
* Undernutrition is common in patients admitted to PICU (20-45%)
  * Obesity increasingly common
* Catabolism with rapid loss of protein stores expected in all
  * Greatest risk for undernourished children, neonates and infants
* Muscle loss and loss of muscle function results in sarcopenia, which increases risks:
  * Prolonged ventilation
  * Acquired pneumonia
  * Prolonged length of stay
  * Mortality
  * Prolonged rehabilitation for survivors

<a id='475d328b-182e-4efc-8511-27707858a2d6'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='7f42e421-4ebe-41c7-b2ad-2bbe9f78f816'></a>

Mehta N, et al. J Pediatr Enteral Nutr. 2017;41:706-42.

<a id='8ac53347-ba7b-435e-8da6-e1165495bc10'></a>

CAPTION ERROR

<a id='5e617827-7373-407b-a487-8b4148ad610a'></a>

APSPEN Guidelines

<a id='1a50a245-0d6a-4893-88f5-6084678541ae'></a>

Clinical Guidelines

# Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION

Journal of Parenteral and Enteral Nutrition
Volume 41 Number 5
July 2017 706-742
© 2017 American Society for Parenteral and Enteral Nutrition and the Society of Critical Care Medicine
DOI: 10.1177/0148607117711387
journals.sagepub.com/home/pen
SAGE

Nilesh M. Mehta, MD¹; Heather E. Skillman, MS, RD, CSP, CNSC²;
Sharon Y. Irving, PhD, CRNP, FCCM, FAAN³; Jorge A. Coss-Bu, MD⁴;
Sarah Vermilyea, MS, RD, CSP, LD, CNSC⁵; Elizabeth Anne Farrington, PharmD, FCCP, FCCM, FPPAG, BCPS⁶;
Liam McKeever, MS, RDN⁷ Amber M. Hall, MS⁸; Praveen S. Goday, MBBS, CNSC⁹;
and Carol Braunschweig, PhD, RD¹⁰

<a id='2bbbc3c2-56c1-4d68-b795-675710961a1c'></a>

* Recommend patients in PICU undergo detailed nutritional assessment within 48 hours of admission
* Have regular reassessment at least weekly
* As lack validated screening tools use weight, height, BMI / weight for length
* Be aware fluid shifts and weight can underestimate protein losses

<a id='4ef3d0f6-04ce-4f50-9637-ef57d607abcb'></a>

NASPGHAN
FOUNDATION

<a id='ac415c24-aba2-4918-9860-936ac7bc4d06'></a>

Mehta N, et al. J Pediatr Enteral Nutr. 2017;41:706-42.

<a id='344a8f70-0c0a-43aa-b2b2-8178a9a6476d'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text 'NASPGHAN' on a blue gradient background, with a curved dark blue line underneath.::>

<a id='331cc9f8-08bb-4eac-b2dd-4ff3367e6ed0'></a>

The Role of Nutrition Support
• Malnutrition is associated with worse outcomes in PICU
• Achieving 60% of energy or protein delivery targets within 7 days after PICU admission associated with lower mortality

Regardless of nutrition support strategy
<::chart: Bar chart showing 60-Day Mortality Rate (%) on the y-axis, ranging from 0 to 16. The x-axis shows different nutrition support strategies and time to achieve targets.

Legend:
option 1-3 days: [x]
option 4-7 days: [x]
option >7 days: [x]

Statistical significance: *P <0.017 (Bonferroni-adjusted)

Groups:
1. Time to achieve 60% of calories EN
   - 1-3 days: n=687, Mortality Rate approx. 2.5%
   - 4-7 days: n=453, Mortality Rate approx. 3.0%
   - >7 days: n=704, Mortality Rate approx. 9.0% (* indicates significance between >7 days and 1-3 days, and between >7 days and 4-7 days)

2. Time to achieve 60% of calories EN + PN
   - 1-3 days: n=785, Mortality Rate approx. 3.5%
   - 4-7 days: n=556, Mortality Rate approx. 4.0%
   - >7 days: n=503, Mortality Rate approx. 9.0% (* indicates significance between >7 days and 1-3 days, and between >7 days and 4-7 days)

3. Time to achieve 60% of protein EN
   - 1-3 days: n=638, Mortality Rate approx. 3.0%
   - 4-7 days: n=445, Mortality Rate approx. 3.5%
   - >7 days: n=761, Mortality Rate approx. 8.5% (* indicates significance between >7 days and 1-3 days, and between >7 days and 4-7 days)

4. Time to achieve 60% of protein EN + PN
   - 1-3 days: n=742, Mortality Rate approx. 4.0%
   - 4-7 days: n=561, Mortality Rate approx. 4.5%
   - >7 days: n=541, Mortality Rate approx. 8.0% (* indicates significance between >7 days and 1-3 days, and between >7 days and 4-7 days)
::>

<a id='f15d7b5c-10fb-44b2-84f6-718e74bfad88'></a>

NASPGHAN
FOUNDATION

<a id='f358b832-038d-4ded-9cb7-644b557bc6dc'></a>

Bechard L, et al. Am J Clin Nutr. 2021;114:1859-67.

<a id='80e20548-68e3-4f2a-b52b-1872f603379f'></a>

CAPTION ERROR

<a id='3a4c9439-efd1-409c-8766-7c242796ad12'></a>

# Route of Nutrition Support in Critical Illness

*   A functional gut should always be used for enteral nutrition (EN), including in critical illness where early enteral nutrition (EEN: 24 - 48h) is preferred and safe

<a id='76fb5d67-949b-4ba9-b82a-479445608606'></a>

<table id="9-1">
<tr><td id="9-2" rowspan="6">• EN Contraindicated if: anatomical disruption, obstruction or ischemia • PN Indicated when cannot use gut</td><td id="9-3">Benefits</td><td id="9-4">Limitations</td></tr>
<tr><td id="9-5">Reduce gut atrophy</td><td id="9-6">Increase gut oxygen needs; can be contraindicated in severe shock</td></tr>
<tr><td id="9-7">Improve gut motility</td><td id="9-8">Risk of Aspiration</td></tr>
<tr><td id="9-9">Reduced infections (enhanced gut immune function and avoidance of translocation)</td><td id="9-a">Frequent interruptions for fasting for diagnostic and other procedures limit efficacy, especially in malnourished patients</td></tr>
<tr><td id="9-b">Less likely to overfeed</td><td id="9-c">Risk of underfeeding</td></tr>
<tr><td id="9-d">Cost effective</td><td id="9-e"></td></tr>
</table>

<a id='0b4abf9f-55d5-4862-9c10-bccfe83065ee'></a>

<::NASPGHAN FOUNDATION logo
: figure::>

<a id='18174267-a247-4665-be05-75e2e764d957'></a>

Ortiz-Reyes L, et al. Critical Care 2022;26:173.
Braunschweig C, et al. Am J Clin Nutr. 2001;74:534-42.

<a id='0c07d79a-e827-4a97-9747-a382f40bd8b6'></a>

CAPTION ERROR

<a id='4c994d3f-3887-4cfd-a038-fa54d081482f'></a>

# What is the Role & Timing of Supplemental PN?

* Based on lack of evidence timing to start supplemental PN when EN intake is insufficient remains controversial
* 2017 Guideline [low quality evidence, weak recommendations]:
  * Start PN If cannot start EN
* Based on a single RCT, do not start PN within 24h of admission
* Based on a single RCT, delay supplemental PN until 1 week after PICU admission for patients with normal nutrition and low risk of worsening nutritional status
* Use caution applying that approach to neonates or children with malnutrition at admission to PICU, who may warrant earlier intervention

<a id='b13a76bf-aa15-4bdc-b9e2-92e1f8b517c1'></a>

NASPGHAN
FOUNDATION

<a id='3554ff71-0809-4d86-97c6-ee308c090ece'></a>

Mehta N, et al. J Pediatr Enteral Nutr. 2017;41:706-42.

<a id='da67c64c-ada0-4f68-ae61-3ad24ae48dd8'></a>

CAPTION ERROR

<a id='e046162b-d22f-41db-8128-8f170bbc2fb7'></a>

The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial

<a id='0227314c-34c5-4710-8ebb-d68274b1be01'></a>

* Multicenter, prospective, randomized, controlled, parallel-group superiority trial (unblinded)
  * 723 patients receiving early PN within 24 hours after ICU admission
  * 717 patients received late PN on day 8 if still <80% of target EN requirements
* All patients started early enteral nutrition (EEN) within 24h
* EN advanced for all per protocol

<a id='6c9d4ab7-b4c8-4f2d-8d8a-4158fa2718e5'></a>

* Newborn – 17 years (45% infants)
  * Preterm neonates were excluded

<a id='2f1ffe74-0c74-46b6-98ed-7c29cbbbfa9e'></a>

<::NASPGHAN FOUNDATION : logo::>

<a id='0d066b91-ae3b-4752-a56f-59ced2938218'></a>

CAPTION ERROR

<a id='1bcee203-252e-4126-ba97-1137a7db0e4a'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, bold font, set against a light blue rectangular background with a subtle gradient, with a dark blue curved line sweeping underneath the text.::>

<a id='ce0c3ed3-400c-4e52-bb26-d88ffc111d43'></a>

The Early versus Late Parenteral Nutrition in the
Pediatric Intensive Care Unit (PEPaNIC) Trial

<a id='4c2fd083-dfde-4561-8955-c180fbb41e4b'></a>

* No differences in mortality
* Late PN group had less infections (10.7% vs 18.5%; p<0.001)
* Late PN group had shorter ICU stay (9.2 vs 6.5d; p<0.001)
* Late PN group had shorter duration ventilation (p=0.001)
* Late PN group had less renal replacement therapy (p=0.04)
* Late PN group had shorter hospital stay (21.3 vs 17.2d; p=0.001)
* Late PN group had more hypoglycemia (9.1% vs 4.8%; p=0.001)

<a id='b95f0f53-c281-4f93-80ac-b6d201d519d9'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='7cdf3c64-235d-40e6-8b73-1a8e864f4419'></a>

CAPTION ERROR

<a id='f2db00dc-2d0a-4f46-82da-7d3bc86955a8'></a>

CAPTION ERROR

<a id='ece592b0-1944-4e35-97fe-cbd3d8c70c6a'></a>

## Limitations of the PEPaNIC Trial

*   77% of late PN group discharged prior to starting PN
*   55% of early PN group discharged by day 4
    *   likely would tolerate EN and not need PN
*   Protein and energy provision was estimated so that both groups may have had either over and under feeding
*   Parenteral nutrient delivery was not standardized
*   Risk of overfeeding particularly high in early PN group
    *   Overfeeding known risk factor for infections with PN
*   Majority sample did not screen at nutritional risk and were normal weight limiting generalizability to malnourished patients

<a id='c3173fb3-692b-4797-b2a3-21033e061e4f'></a>

NASPGHAN
FOUNDATION

<a id='29a08c6e-fc11-496a-aed2-897df6d51e80'></a>

Fivez T, et al. NEJM 2016;374:1111-22.

<a id='09ed689c-bc1a-4927-b739-43b203f282a1'></a>

CAPTION ERROR

<a id='973642f0-a912-472e-be69-79a7d5308232'></a>

# Risks of Underfeeding in Critical Illness
* Hypoglycemia
* Progressive sarcopenia in PICU
* Prolonged ventilation due to sarcopenia
* Increased infection risk
* Poor wound healing
* Prolonged sarcopenia post PICU stay requiring rehabilitation
* Potential to adversely impact neurocognitive and psychomotor development

<a id='2a201b98-5683-4d3f-84ac-cb01c213131a'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='61b07b83-4ae9-4c66-a654-bab22fc309d2'></a>

CAPTION ERROR

<a id='3450a073-58a9-4210-82e9-003e96ffab1b'></a>

# Risks of Overfeeding in Critical Illness

* Hyperglycemia, which increases risk of sepsis and poor wound healing
* Hypertriglyceridemia
* Hepatic steatosis
* Cholestasis
* Uremia
* Ventilator dependency with hypercapnia from glucose overfeeding

<a id='ebe8296e-dc09-4286-93c8-17d945047352'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='75ede4e0-2cc0-40ee-9fdd-1ee153f886ad'></a>

CAPTION ERROR

<a id='520a7aaf-c924-47e1-9aec-cdd772a08002'></a>

Until the Best Approach is Known Consider an Individualized Approach?

<a id='a2f0f059-dcf2-499d-b3de-fc51156d622c'></a>

* Delay PN 7 days if risk
of overfeeding
* Only use if not meeting
60% of EN goals and
advancing
* Consider supplemental
PN 3-5 days if risk of
underfeeding

<a id='ca95a91e-f720-4ff3-b331-75425286bc38'></a>

<::A line graph titled "High risk of overfeeding with PN" (left shaded area) and "High risk of underfeeding without PN" (right shaded area). The y-axis is labeled "Energy" and the x-axis is labeled "Days" with numerical markers at 1, 2, 3, 6, and 7. The y-axis has a break symbol. Three main lines are plotted:
- A black solid line representing "Total energy expenditure", which starts high, peaks around day 2, and then gradually decreases.
- A gray solid line representing "Endogenous energy production", which starts lower than total energy expenditure, peaks around day 2, and then gradually decreases, staying below the total energy expenditure line.
- A black dashed line representing "Early EN" (Enteral Nutrition), which starts at a low level, increases in a step-wise manner around day 2, and then levels off until day 3.
- A gray dashed line representing "Supplemental PN" (Parenteral Nutrition), which starts around day 3 at a higher level than Early EN, and then remains constant.

Two upward-pointing arrows are located below the x-axis, labeled "Calorimetry" at day 3 and day 6.
: chart::>

<a id='38074ab1-b8a6-4b2b-8566-7c62d62f9034'></a>

NASPGHAN
FOUNDATION

<a id='5d2f3cdf-83fb-41dc-9d65-4552fe02618f'></a>

Jiminez L, et al. Curr Opin Clin Nutr Metab Care 2017;20:227-31.

<a id='bf7537cc-b8b4-408e-a8e9-f85256da670b'></a>

CAPTION ERROR

<a id='4013e2c5-704d-43d4-9561-ebdf72069d35'></a>

# Parenteral Energy Requirements

*   Energy requirements are highly variable in PICU
    *   Often lower than predicted, e.g., sedation, ventilation, paralysis, PN (NPO)
*   Can be higher, e.g., CNS injury with dysautonomia, burns

<a id='7d9cc129-1339-410d-be17-41e60dae8308'></a>

* Predictive equations for energy have limited accuracy
* But due to lack of access to calorimetry are widely used

<a id='18506370-2eb1-4c9e-bb9c-5ae50898ab84'></a>

<::transcription of the content
: NASPGHAN
FOUNDATION::>

<a id='aa3cede0-3c09-4f50-9cfd-9ef64ce0869e'></a>

Mehta N, et al. J Parenter Enteral Nutr. 2017;41:706-42.

<a id='946ea377-bb65-477c-9eab-4427c320aa33'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, bold font, set against a light blue to white gradient background, with a curved dark blue line underneath the text.::>

<a id='eb313339-159b-4061-9a51-49eb7a20c61b'></a>

# Parenteral Energy Requirements – Cont'd
* 2017 Guideline [low quality evidence, weak recommendations]
  * Use calorimetry to guide energy goals
  * In the absence of calorimetry use Schofield/FAO/WHO/UNU equations
    * NOT Harris Benedict or RDA
    * DO NOT add stress factors
* Target at least 2/3 of goal energy be end of first week in PICU
  * Individualize approach according to baseline nutrition and risk for over or underfeeding

<a id='e25b3f5b-1288-42ec-8a78-3c66b8222199'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background::>

<a id='c19d4ca7-6214-46b1-9887-79e0006cfb6c'></a>

Mehta N, et al. J Parenter Enteral Nutr. 2017;41:706-42.

<a id='e1ca1232-75cd-4af2-87c6-8f02a892ae02'></a>

CAPTION ERROR

<a id='2793822a-e1f9-40a1-9b59-9a75f54357a9'></a>

Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU

<a id='ed038f02-3c01-49a6-aa42-5a215378ad6f'></a>

1. Malnutrition (BMI<5th percentile) or overweight (BMI > 85th)
2. > 10% weight gain or loss during PICU stay
3. Failure to consistently meet prescribed caloric goals
4. Failure to wean or escalation in respiratory support
5. Need for muscle relaxants > 7days
6. Need for ventilation > 7days
7. CNS trauma (injury, hypoxia, ischemia) with dysautonomia
8. Oncologic diagnosis
9. PICU stay > 14 days
10. Suspect Hypometabolism (e.g., hypothermia/cooling, drug induced coma) or Hypermetabolism (e.g., SIRS, status epilepticus, hyperthermia)

<a id='341c4f41-aa98-4b2a-8f94-cf85a7c269b9'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='f94e7f7a-c105-4ccd-8a98-134856b5f892'></a>

Albert B, et al. Minerva Anestesiologica 2021;87:1025-33.

<a id='9f86c5d3-5287-4de1-8c5c-5016e177978d'></a>

CAPTION ERROR

<a id='c9ca2bde-030e-4df5-b334-461ce784bcbf'></a>

# Parenteral Protein Requirements
* Both protein breakdown and synthesis are increased in critical illness
  * Negative nitrogen balance results
* Protein supply is critical and often underestimated
  * Bedside tools to evaluate nitrogen balance limited (especially in renal impairment)
  * Increased requirement in burns, gastrointestinal losses, open wounds, continuous renal replacement therapy
* 2017 Guideline [moderate quality evidence, strong recommendations]
  * Provide a minimum of 1.5g/kg/day protein (and more in infants)
  * Do not use RDA (recommended daily allowance) as will be insufficient

<a id='06723d1a-5146-4226-9f68-10c008ee6c22'></a>

NASPGHAN
FOUNDATION

<a id='766aee65-ad65-4436-9bde-718fd4688a0f'></a>

Mehta N, et al. J Parenter Enteral Nutr. 2017;41:706-42.

<a id='2c2554c2-863b-4461-9b09-40a11a496ed4'></a>

::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, and bold font, set against a light blue to purple gradient background, with a dark blue curved line underneath the text.::

<a id='2c53708f-2520-483e-b64c-07fc4cc8d684'></a>

Both Important to Achieve Positive Nitrogen Balance

<a id='89781061-389b-4250-b778-40b846be5668'></a>

<::scatter plot
: The plot shows Protein balance (g/kg/day) on the y-axis against Protein intake (g/kg/day) on the x-axis. The y-axis ranges from -2.00 to 2.00, with major ticks at -2.00, -1.00, .00, 1.00, and 2.00. The x-axis ranges from .0 to 3.5, with major ticks at .0, .5, 1.0, 1.5, 2.0, 2.5, 3.0, and 3.5. A dotted horizontal line is present at y = .00. There are 10 data points scattered across the plot, and a solid upward-sloping regression line passes through the data points, indicating a positive correlation between protein intake and protein balance.
::>

<a id='c46a21ae-336a-49e6-9564-c765f864904c'></a>

<::A scatter plot showing the relationship between Energy intake (kcal/kg/day) on the x-axis and Protein balance (g/kg/day) on the y-axis. The x-axis ranges from approximately 20.0 to 120.0, and the y-axis ranges from -2.00 to 2.00. Data points are scattered across the plot, and a solid black line indicates a positive linear trend. A dotted horizontal line is present at Protein balance = 0.00.::>

<a id='a0d41c26-bb7a-414a-b65e-539bc4d35dc4'></a>

* Systematic review 9 studies 1981-2011 (n=347) children with heterogenous diagnoses admitted to PICU (who had measured protein balance)
* Positive balance with protein intake > 1.5g/kg/d or energy intake > 57Kcal/kg/day

<a id='70885c5c-7f1f-4f3a-99e5-9bb409f778be'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='b1cce560-23f4-4887-b3bf-ec0e97eb9e8e'></a>

Bechard L, et al. J Pediatr. 2012;161:333-9.

<a id='dc5a7a3b-b5fc-4885-abac-33fd12e2d614'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features bold, dark blue text "NASPGHAN" on a light blue gradient background with a dark blue curved line underneath.::>

<a id='40102e10-f4c1-46d1-95a7-caad56fbbff9'></a>

# Extracorporeal Membrane Oxygenation (ECMO)
* Indicated for severe cardiac and/or respiratory failure
* Evidence base limited to expert opinion and case series
  * EN safe for 75-90% of patients on ECMO
  * Feeding intolerance is common, up to 50%

<a id='07eed27d-b287-494b-965c-3d201e482880'></a>

* Acknowledged risk for gut hypoperfusion, although severe Gl complications reportedly rare
* PN (total parenteral nutrition with nil enteral) may be preferred in unstable patients with escalating inotropes or concerning symptoms like bilious emesis, GI bleeding or increasing abdominal distention

<a id='5756857a-fd31-4cc7-8afa-3e0759e10a1a'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='8aa52439-fb90-4dd0-b35b-0402c5b7518f'></a>

Armstrong L, et al. J Peditatr Enteral Nutr. 2018;42:1133-8.
Farr B, et al. Nutr Clin Pract. 2018;33:747-53.

<a id='a6e5fb5d-8286-43ef-9d55-58f90fc47c1c'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='14afe8bd-8dd9-4613-941f-03aa37fff3da'></a>

ECMO – Cont'd

*   REE not readily measured or predicted by current equations
*   EN has risk of _underfeeding_ given feeding intolerance
*   Supplemental PN can increase protein and energy delivery, but risk of _overfeeding_
*   Start supplemental PN 5-7 days well nourished or 3-5 days in malnourished children

<::Energy Intake (kcal/kg/day) over Time since ECMO Cannulation (days) chart, showing Total, PN, and EN values. The x-axis ranges from 0 to 14 days, and the y-axis ranges from 0 to 80 kcal/kg/day. Total and PN intake increase significantly over the first 7 days, while EN remains low.::>

<::Protein Intake (g protein/kg/day) over Time since ECMO Cannulation (days) chart, showing Total, PN, and EN values. The x-axis ranges from 0 to 14 days, and the y-axis ranges from 0 to 3 g protein/kg/day. Total and PN intake increase significantly over the first 7 days, while EN remains low.::>

<a id='9cea7977-334e-4c1f-a526-f5bdec783274'></a>

NASPGHAN
FOUNDATION

<a id='dc2a00e8-7240-442c-94b2-f2a7d22cec77'></a>

Armstrong L, et al. J Pediatr Enteral N. 2018;42:1133-8.

<a id='68da8915-9a7e-4c89-a59d-90ad0bf56a22'></a>

CAPTION ERROR

<a id='c50c076a-6cfd-4bd9-8553-b5dcfdc6a78b'></a>

Chylothorax

* Common complication in PICU after cardiac surgery, ~5%
* Majority can be managed medically: median chain triglyceride (MCT) enriched EN first line treatment
  * No RCTs comparing MCT-rich EN to PN and nil per os
* PN (with lipids) may be indicated if refractory to EN or high-volume losses >10ml/kg/day
  * More than 80% effective, without further medication or surgery
* Risk of nutritional losses and immunosuppression
  * Chylous fluid has 20-60g/L protein, electrolytes, trace minerals, immune cells and immunoglobulins
  * Monitor for EFAD if extended use of MCT-rich EN, although rare

<a id='4b2e9c5d-7ae2-49a5-bd27-06c6809baf7f'></a>

NASPGHAN
FOUNDATION

<a id='52c33fb5-0141-48fc-ab40-2d650c45875e'></a>

Duletzke N, et al. Nutr Clin Pract. 2023;38:557-63.

<a id='e1fd8fb6-681d-4477-96b6-361f14d34554'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, set against a light blue rectangular background with a gradient, and a dark blue curved line underneath the text.::>

<a id='2bb77b82-5269-4d18-8d1c-9b9804464171'></a>

## Gastrointestinal Surgery & Ostomies

*   Massive intestinal resection induces major functional and metabolic changes in the GI tract
    *   Loss of inhibitory reflexes of the enteric nervous system including cologastric and ileogastric reflexes, accelerating intestinal motility
    *   Decrease in enterohormones leading to accelerated gastric emptying and increased gastric secretion
    *   Bile acid loss
*   Major net loss of fluids and electrolyte via end-jejunostomy
    *   Losses worsened by oral intake
*   PN mixture must meet higher hydration needs and compensate nutrition losses

<a id='03b4a658-7028-453d-9649-a6ea74299579'></a>

<::NASPGHAN FOUNDATION logo
: figure::>

<a id='d11366bb-d480-4173-ae07-b5f36eb30491'></a>

Sobocki J, et al. British J Nutr. 2021;125:1125-31.
Nightingale J, et al. Lancet 1990;336:765-8.

<a id='0e2b59d0-9edb-49cd-be7e-134bdc25b7a6'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='4536013b-bbad-4d12-aca8-cb45d4da1025'></a>

Consider Site Specific Effects of Intestinal Resection
for GI Function (and Stoma Losses) and GI Hormones

<a id='5937158a-4729-4e72-941c-f11af9126cd4'></a>

Nutrient Absorption Sites
Duodenum/Proximal Jejunum
• macronutrients
• iron
• folate
• calcium
• vitamins/minerals

Jejunum/Proximal Ileum
• macronutrients
• calcium
• vitamins/minerals

Distal Ileum
• bile salts
• vitamin B₁₂
• SCFA

Colon
• SCFA
• minerals
• vitamin K

<::diagram of the human digestive system: The diagram illustrates the liver, stomach, pancreas, small intestine (duodenum, jejunum, ileum), and large intestine (colon). Arrows connect specific regions of these organs to the adjacent lists, indicating their roles in nutrient absorption and mediator release.::>

Mediator Release Sites
Stomach
• gastrin
• ghrelin

Duodenum
• cholecystokinin
• secretin
• GIP
• VIP

Jejunum/Ileum
• neurotensin

Distal Ileum/Colon
• peptide YY
• GLP-1
• GLP-2

<a id='67e909ae-c090-40d5-9637-a612f9d34e02'></a>

NASPGHAN
FOUNDATION

<a id='05cd1478-6d19-49c3-92e1-2297fe7985b9'></a>

CAPTION ERROR

<a id='5f4c4337-499a-4bb3-afc4-b7d001f219fa'></a>

CAPTION ERROR

<a id='1f89750a-6015-42c6-918f-6460d46f9fed'></a>

Gastrointestinal Surgery & Ostomies

<a id='fa49b5d2-b0bd-42b8-b317-a36c79e482f0'></a>

* PN considerations to compensate for high losses in proximal ostomies
* Fluid
* Sodium; patients will not grow until adequately supplemented with sodium. Recommend following urine sodium to guide sodium replacement.
* Potassium
* Bicarbonate; incompatible with PN so replaced as acetate in PN; in end stage liver disease may have difficulty converting acetate to bicarbonate
* Zinc
* Iron; increased needs in ex-preterm, with chronic GI blood loss and extensive proximal small bowel loss; can be added to PN, but not with sepsis or 3:1 solutions
* Copper; standard supplementation may be inadequate

<a id='02e77631-0e63-4bae-8749-15e8015723aa'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='055f35bd-4eaf-40f9-a04a-19b3423df2ab'></a>

Sobocki J, et al. British J Nutr. 2021;125:1125-31.
Nightingale J, et al. Lancet 1990;336:765-8.
Adler A, et al. Nutr Clin Pract. 2020;35:724-8.

<a id='557063b6-cb58-4ccb-ab22-a5d82f7ea888'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line beneath it.::>

<a id='6f8a5130-5d27-483d-9fea-6f551450a09a'></a>

Malnutrition in Pediatric Chronic Liver Disease

<a id='2a42223a-b158-4da1-8bee-c50f39f15c0b'></a>

<::Visual content: diagram
- **Decreased energy intake**
  - Anorexia
  - Changes in taste perception
  - Early satiety
  - Nausea / vomiting
- **Increased energy intake**
  - Increased energy requirement up to 150% EAR
  - Hypermetabolic state in end-stage liver disease
  - Sequelae of CLD (i.e., peritonitis, variceal bleeding)
  - Increased pro-inflammatory cytokines
- **Endocrine dysfunction**
  - Impaired GH / IGF-1 axis
  - Decreased IGF-1 formation
- **Malabsorption and disordered substrate metabolism**
  - Carbohydrate - hypoglycemia from decreased glycogen stores, hepatocyte loss in fulminant liver failure
  - Proteins - increased protein catabolism, impaired protein synthesis
  - Fats - malabsorption from decreased bile delivery to small bowel, unconjugation of bile salts with bacterial overgrowth (in children with Kasai portoenterostomy), congested intestinal mucosa.
::>

<a id='14cb15d4-18c4-4b9c-bf32-a37e4c5ff771'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='a4bc45e0-a29e-4ccf-98dd-4944f85c7295'></a>

Yang CH, *et al*. *Nutrients* 2017;9:1127.

<a id='faed317b-e10f-4d16-bfbc-ef277376dadd'></a>

<::NASPGHAN logo with a curved line underneath : figure::>

<a id='1f9ba361-ea0f-47a9-9a46-bdda8a355940'></a>

# Liver Disease

*   Supplement
    *   Zinc (if deficient)
    *   Potassium (especially if on diuretics)
    *   Fat soluble vitamins D, E, K (if deficient)
    *   Protein (if hypoalbuminemic and not encephalopathic)
*   Encephalopathy
    *   Reduce protein
    *   Monitor ammonia
*   Cholestasis
    *   Restrict copper, manganese since they are secreted in bile
    *   Adjust lipids: consider fish oil lipid emulsion (Omegaven®)
*   Immunosuppressant medications can affect nutritional status

<a id='f7c43f98-ee72-45e0-8dc0-9032aabcade6'></a>

NASPGHAN
FOUNDATION

<a id='f14e934c-3da2-4f5f-99c5-e2eb2ad92c3c'></a>

CAPTION ERROR

<a id='b8e2da49-309b-4d77-976d-852151a34c32'></a>

Vitamins: Lab Markers and Dosing Recommendations

<a id='68cabcfa-bfb0-47a3-8bd6-ceea805acb23'></a>

<table id="30-1">
<tr><td id="30-2">Vitamin A</td><td id="30-3">Vitamin D</td></tr>
<tr><td id="30-4">Laboratory Markers</td><td id="30-5">Laboratory Markers</td></tr>
<tr><td id="30-6">Serum retinol level</td><td id="30-7">Serum 25-OHD</td></tr>
<tr><td id="30-8">If available RDR</td><td id="30-9"></td></tr>
<tr><td id="30-a">Recommendations</td><td id="30-b">Recommendations Cholecalciferol</td></tr>
<tr><td id="30-c">1000 IU/kg/day, up to</td><td id="30-d">•Weight >40kg</td></tr>
<tr><td id="30-e">25,000 IU of water miscible formulations</td><td id="30-f">• Serum level <10 ng/mL: 5000 IU/day</td></tr>
<tr><td id="30-g">• <10 kg: start with 5000 IU/day • >10 kg: start with 10,000 IU/day</td><td id="30-h">• Serum level 11-19 ng/mL: 4000 IU/day • Serum level 20-29 ng/mL: 3000 IU/day</td></tr>
<tr><td id="30-i"></td><td id="30-j">•Weight <40kg •120-200 IU/kg</td></tr>
</table>
<table id="30-k">
<tr><td id="30-l">Vitamin E</td><td id="30-m">Vitamin K</td></tr>
<tr><td id="30-n">Laboratory Markers Serum tocopherol level If available α-tocopherol/total lipids ratio Recommendations D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) 15-25 IU/kg/day</td><td id="30-o">Laboratory Markers PT/INR If available PIVKA-II Recommendations 2.5-5 mg/day 2-7 times weekly; 1-10 mg intravenous as needed</td></tr>
</table>

<a id='74a52625-a4c9-455d-b30b-7c6e2a6a45c5'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='6a703b01-bcbe-4086-8a77-4e3dd3f60458'></a>

Yang CH, *et al*. *Nutrients* 2017;9:1127.

<a id='245731eb-9ce5-4fdb-b4af-893f0d6c577d'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue text "NASPGHAN" on a light blue gradient background, with a curved dark blue swoosh underneath.::>

<a id='c80b44af-7c2e-406b-a887-0dd63bdd8ef6'></a>

Nutritional Needs of Children With CLD Before and After Liver Transplant

<a id='d7059cf7-78e3-4b6e-b40a-feab153267c0'></a>

<::Liver Transplant
: chart::>

Before
ENERGY INTAKE
• 130-150% EAR
CARBOHYDRATES
• 15-20 g/kg/day given as glucose polymers
PROTEINS
• 3-4 g/kg/day; if acutely encephalopathic may temporarily
  restrict to <2 g/kg/day. BCAA-enriched formula can be
  considered
FATS
• 8 g/kg/day, with 30-50% as MCT
• Infants can receive formula containing up to 75% MCT; higher
  MCT content may result in essential fatty acid deficiency

After
ENERGY INTAKE
• 120% EAR
CARBOHYDRATES
• 6-8 g/kg/day given as glucose polymers
PROTEINS
• 2.5-3 g/kg/day
FATS
• 5-6 g/kg/day LCT
• Children receiving high MCT-containing supplementation pre-
  transplant can transition to standard formula once bile flow is
  established post-transplant

<a id='38d9d7dc-2df0-42a3-9377-cdbd44629137'></a>

<::NASPGHAN FOUNDATION logo with blue gradient background.: figure::>

<a id='6054d110-983f-4453-bf7b-94bc8b3ddaad'></a>

Yang CH, et al. Nutrients 2017;9:1127.

<a id='5173a025-a7b4-4d40-97be-044847c02bfa'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='40915e95-f7f1-4f94-a2c4-4ec41049b537'></a>

# Nutritional Side-Effects of Immunosuppressive Meds

<a id='6955b4b4-59a4-4d45-a5a3-64aa9f062aef'></a>

<table id="32-1">
<tr><td id="32-2">Immunosuppressant</td><td id="32-3">Nutritional Side-Effects</td></tr>
<tr><td id="32-4">Calcineurin inhibitors (FK, tacrolimus, cyclosporine)</td><td id="32-5">Hyperlipidemia, Hyperglycemia Hypomagnesemia, Hyperkalemia Hypertension Avoid grapefruit</td></tr>
<tr><td id="32-6">Corticosteroids (prednisone, methylprednisolone)</td><td id="32-7">Hyperglycemia, Hyperlipidemia Sodium retention, Hypertension Increased appetite, Weight gain Muscle wasting Peptic ulcer disease Impaired wound healing Electrolyte disturbances</td></tr>
<tr><td id="32-8">Mycophenolate (MMF)</td><td id="32-9">Diarrhea, Nausea</td></tr>
<tr><td id="32-a">Azathioprine</td><td id="32-b">Nausea, vomiting, sore throat, altered taste acuity</td></tr>
<tr><td id="32-c">Sirolimus</td><td id="32-d">Hyperlipidemia, GI symptoms</td></tr>
</table>

<a id='38c493a5-1f8e-4c19-a0f4-301a507b7ad7'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='77de559e-8542-4e35-9dcb-dab1a6cc182d'></a>

Ikizler TA, et al. Am J Kidney Dis. 2009;76(3):S1-S107.

<a id='67f6154d-8525-4def-86e7-e68541664947'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='4be2eaef-a4e9-4e28-bfc6-edce47587c94'></a>

# Renal Disease

* When to consider PN
  * Peritoneal dialysis complicated by ileus or peritonitis
  * Critically ill patients on hemodialysis
  * Severe malnutrition, intolerance of enteral feeds
  * Intestinal obstruction (mechanical or pseudo-obstruction)
* Acute Kidney Injury (AKI)
  * Fluid intake is often reduced
  * Volume available for PN can impact on caloric intake
  * Protein intake often restricted to meet minimum requirements
  * Electrolytes based on serum levels

<a id='82f0e235-9f73-490f-8fa5-9a4eb768d67a'></a>

NASPGHAN
FOUNDATION

<a id='c1911f01-d3ba-43c8-a8b1-cb1f45d96e7c'></a>

CAPTION ERROR

<a id='4578e594-348f-4d00-bd88-879567139717'></a>

# Renal Disease – Cont'd

*   On dialysis
    *   Protein losses are increased by dialysis
    *   Dialysis removes excess urea
    *   Increase fluid, calorie, and protein provision
    *   No longer need to restrict or reduce protein provision

<a id='2cff771c-c428-460e-8e19-b9d5f2231618'></a>

NASPGHAN
FOUNDATION

<a id='8d1ffb9f-912f-4e63-8912-9ee9467ae407'></a>

Raina F, et al. Nat Rev Nephrol. 2020;16:471-82.

<a id='77ae7896-e6e3-43e9-a399-07f455e136c0'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features bold, italicized, dark blue text "NASPGHAN" on a blue gradient background with a curved line underneath.::>

<a id='ca11c689-641f-49d2-8455-97f045318885'></a>

Renal Disease Nutrient Recommendations

<a id='fae0c031-b1a5-4dab-9bab-895ad30ee7b9'></a>

<table id="35-1">
<tr><td id="35-2">Restriction may be required</td><td id="35-3">Supplementation may be required</td></tr>
<tr><td id="35-4">Deduct dialysate glucose when calculating glucose infusion rate (GIR)</td><td id="35-5">Protein (increased losses with dialysis)</td></tr>
<tr><td id="35-6">Total fluids (based on fluid status and dialysis settings)</td><td id="35-7">Alkali due to increased losses in 'nonoliguric' renal failure (e.g., congenital hydronephrosis, renal dysplasia)</td></tr>
<tr><td id="35-8">Sodium (give in small amounts due to diminished excretion)</td><td id="35-9">Sodium due to increased losses in 'nonoliguric' renal failure (e.g., congenital hydronephrosis, renal dysplasia)</td></tr>
<tr><td id="35-a">Potassium (give in small amounts due to diminished excretion)</td><td id="35-b">Potassium (if on diuretics or depending on dialysate)</td></tr>
<tr><td id="35-c">Phosphorous (give in small amounts due to diminished excretion)</td><td id="35-d"></td></tr>
<tr><td id="35-e">Vitamin C to <100 mg/day in pts with hyperoxaluria</td><td id="35-f"></td></tr>
<tr><td id="35-g">Lipids in patients with hyperlipidemia of renal failure</td><td id="35-h"></td></tr>
</table>

<a id='6fcbda58-eba8-42da-b8e6-c27d78a45f90'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='0a8c6f76-a96d-427f-a9de-bbcb2f59f584'></a>

Wong Vega M, et al. Nutr Clin Pract. 2023;38:S139-57.
Raina R, et al. Nat Rev Nephrol. 2020;16:471-82.

<a id='9cf96a6c-5294-4e72-83a0-14d5be52bd60'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, and bold font, set against a blue gradient background that fades from a darker blue at the top to a lighter blue at the bottom, with a curved dark blue line sweeping underneath the text.::>

<a id='e67746df-a19e-4d91-a065-80e40c98f94a'></a>

Estimated Energy and Protein Requirements in Children with Renal Disease

<a id='70e19a4b-88c3-48a7-b0b9-028d4e7d90b4'></a>

<table id="36-1">
<tr><td id="36-2" rowspan="2">Age Group</td><td id="36-3" colspan="2">Pre-Dialysis (gray button)</td><td id="36-4" colspan="2">Hemodialysis</td><td id="36-5" colspan="2">Peritoneal Dialysis</td></tr>
<tr><td id="36-6">Energy Kcal/kg/d</td><td id="36-7">Protein g/kg/d</td><td id="36-8">Energy Kcal/kg/d</td><td id="36-9">Protein g/kg/d</td><td id="36-a">Energy Kcal/kg/d</td><td id="36-b">Protein g/kg/d</td></tr>
<tr><td id="36-c">0 - 6 m</td><td id="36-d">100 - 110</td><td id="36-e">1.5 - 2.2</td><td id="36-f">100 - 110</td><td id="36-g">1.6</td><td id="36-h">100-110</td><td id="36-i">1.8</td></tr>
<tr><td id="36-j">6 - 12 m</td><td id="36-k">95 - 105</td><td id="36-l">1.2 - 1.7</td><td id="36-m">95 - 105</td><td id="36-n">1.3</td><td id="36-o">95-105</td><td id="36-p">1.5</td></tr>
<tr><td id="36-q">1 - 3 y</td><td id="36-r">90</td><td id="36-s">1.05 - 1.5</td><td id="36-t">90</td><td id="36-u">1.15</td><td id="36-v">90</td><td id="36-w">1.3</td></tr>
<tr><td id="36-x">4 – 10 y</td><td id="36-y">70</td><td id="36-z">0.95 – 1.35</td><td id="36-A">70</td><td id="36-B">1.05 – 1.6</td><td id="36-C">70</td><td id="36-D">1.1-2.0</td></tr>
<tr><td id="36-E">11 – 14 y (boys)</td><td id="36-F">55</td><td id="36-G">0.95 – 1.35</td><td id="36-H">55</td><td id="36-I">1.05 – 1.4</td><td id="36-J">55</td><td id="36-K">1.1-1.8</td></tr>
<tr><td id="36-L">11 – 14 y (girls)</td><td id="36-M">47</td><td id="36-N">0.95 – 1.35</td><td id="36-O">47</td><td id="36-P">1.05 – 1.4</td><td id="36-Q">47</td><td id="36-R">1.1-1.8</td></tr>
<tr><td id="36-S">15 – 18 y (boys</td><td id="36-T">45</td><td id="36-U">0.85 – 1.2</td><td id="36-V">45</td><td id="36-W">0.95 – 1.3</td><td id="36-X">45</td><td id="36-Y">1.0-1.5</td></tr>
<tr><td id="36-Z">15 – 18 (girls)</td><td id="36-10">40</td><td id="36-11">0.85 – 1.2</td><td id="36-12">40</td><td id="36-13">0.95 – 1.2</td><td id="36-14">40</td><td id="36-15">1.0 - 1.5</td></tr>
</table>

<a id='85ab77d3-ba78-4f3f-bad2-116c9c6d1ca3'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='1c72df98-1a03-4ea4-9055-7a646a184973'></a>

National Kidney Foundation. *Am J Kidney Dis.* 2009;53(Suppl 2):S1-S124.

<a id='bf73bd4d-2ab1-4365-a3f0-f60d43e3c1e5'></a>

CAPTION ERROR

<a id='c656f343-de19-4ce3-b54c-190d5a31b5e9'></a>

Micronutrients in AKI: Energy

<a id='b20169f0-40c7-4b79-add8-73c39f2f4e18'></a>

<table id="37-1">
<tr><td id="37-2">Macronutrient</td><td id="37-3">AKI, no RRT</td><td id="37-4">CRRT</td><td id="37-5">PIRRT</td><td id="37-6">HD</td><td id="37-7">PD</td></tr>
<tr><td id="37-8">Energy</td><td id="37-9" colspan="5">Dictated by disease state, malnutrition, and illness severity</td></tr>
<tr><td id="37-a">Key considerations</td><td id="37-b">N/A</td><td id="37-c" colspan="2">• High removal rates of levocarnitine may influence metabolism of free fatty acids • Largely dependent o use of citrate-based anticoagulation and dextrose solutions used within respective institutions • Larger patients likely receive more significant exposure • May be CRRT dose dependent. Higher dose may clear more nonnutritive fluids into effluent than lower doses. • Glucose-free replacement fluids may lead to energy removal • Hyperosmolar, hyperglycemic states may contribute to energy deficit</td><td id="37-d">N/A</td><td id="37-e">• Dextrose is present in dialysate but assessment of exposure cannot be performed without assessment of membrane transporter status • Monitor weight trends and adjust nutrition support accordingly</td></tr>
</table>
Note: Suggestions within this table are initial recommendations that should be titrated based on patient progress and reassessment of the patient's nutrition status and medical goals of care.

<a id='b9f98a7e-b9c3-4f10-b3f9-b5191a8e5cdc'></a>

<::transcription of the content
: NASPGHAN FOUNDATION logo::>

<a id='3762247d-e75c-4fce-9b4c-8b08cf6dedf4'></a>

CAPTION ERROR

<a id='cee2d256-1a4b-420e-b80d-732f9d032183'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, bold font, set against a rectangular background that transitions from a darker blue at the top to a lighter blue at the bottom, with a dark blue curved line underneath the text.::>

<a id='5c338d8f-6e60-4c6c-94ca-aeed05b9c542'></a>

Micronutrients in AKI: Protein

<a id='2b31a540-ecda-4b86-9928-6dbfb2b05ca8'></a>

<table id="38-1">
<tr><td id="38-2">Macronutrient</td><td id="38-3">AKI, no RRT</td><td id="38-4">CRRT</td><td id="38-5" colspan="2">PIRRT</td><td id="38-6">HD</td><td id="38-7">PD</td></tr>
<tr><td id="38-8">Protein</td><td id="38-9">DRI / age minimum</td><td id="38-a" colspan="3">≥ 2.5 g/kg/day protein or ASPEN/ age + additional 10%–20% to account for removal</td><td id="38-b">ASPEN / age + 0.1 g/kg/day</td><td id="38-c">ASPEN / age + 0.3 g/kg/day</td></tr>
<tr><td id="38-d">Key considerations</td><td id="38-e">• Temporary protein restrictions may be implemented if AKI recovery expected soon • Inability to obtain dialysis access may limit ability to provide goal protein intake</td><td id="38-f" colspan="2">• No expectation the SUN levels are low or normal • 2.5 g/kg/day is extrapolated from adults</td><td id="38-g">• May require less protein than CRRT, given intermittent nature</td><td id="38-h">• Value is extrapolated from adults receiving HD 3×/week • If HD frequency expected to be higher, adjust for increased frequency</td><td id="38-i">• Values are extrapolated from populations with chronic ESRD</td></tr>
</table>
Note: Suggestions within this table are initial recommendations that should be titrated based on patient progress and

<a id='af17384c-1f16-43d1-bdee-e098495d7d6f'></a>

Note: Suggestions within this table are initial recommendations that should be titrated based on patient progress and reassessment of the patient's nutrition status and medical goals of care.

<a id='94f7d8ce-fce3-46e0-b785-038b90701fd5'></a>

<::NASPGHAN FOUNDATION logo : figure::>

<a id='48896cf6-8ec6-4cfd-925c-1abeaf5b9dce'></a>

Wong Vega M, et al. Nutr Clin Pract. 2023;38:S139-57.

<a id='16338fd8-9722-4408-a9d0-202f01105cdf'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='ae3e9d54-3f8d-4cf7-ba10-f80a59ce16ad'></a>

Micronutrients in AKI: Fluid

<a id='970982ba-d969-4b10-b903-a6a3e29bcfa8'></a>

<table id="39-1">
<tr><td id="39-2">Macronutrient</td><td id="39-3">AKI, no RRT</td><td id="39-4">CRRT</td><td id="39-5">PIRRT</td><td id="39-6">HD</td><td id="39-7">PD</td></tr>
<tr><td id="39-8">Fluid</td><td id="39-9">Largely dependent on responsiveness to diuretics</td><td id="39-a">• Unrestricted • May be temporarily restricted around initial start</td><td id="39-b">Largely dependent on length of treatment</td><td id="39-c">• < 13-ml/kg/h per treatment • Limit myocardial stunning; may be lower in hemodynamically unstable patients</td><td id="39-d">Unpredictable</td></tr>
<tr><td id="39-e">Key considerations</td><td id="39-f" colspan="5">• Follow I/Os and fluid balance goals accounting for urine output, volume of medications, and blood products • Concentrate nutrition support when able if not achieving fluid balance goals</td></tr>
</table>

<a id='b47bad19-c02d-4a48-a86c-47e919ffd0a7'></a>

Note: Suggestions within this table are initial recommendations that should be titrated based on patient progress and reassessment of the patient's nutrition status and medical goals of care.

<a id='b0ff0a7c-703a-4a5f-bf27-c8615c54bfc3'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='ac53fd7c-0a16-4a25-92cd-f14401f4caea'></a>

Wong Vega M, et al. Nutr Clin Pract. 2023;38:S139-57.

<a id='cdf75f0c-f787-4117-842c-ebb2a60a84c3'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features bold, italicized, dark blue text "NASPGHAN" on a light blue rectangular background with a subtle gradient, and a dark blue curved line sweeping underneath the text.::>

<a id='e2d56c5d-c8dc-4008-a7e4-b8363b72f829'></a>

## Inborn Errors of Metabolism

*   PN should be initiated quickly during metabolic stressors
    *   Promote anabolism
    *   Diminish catabolism
*   Use PN short-term and start enteral nutrition (EN) as soon as clinically feasible
*   Metabolic parameters should be monitored closely with adjustment of type and amount of protein when necessary
*   Common metabolic stressors
    *   Trauma
    *   Burns
    *   Gastrointestinal (pancreatitis, ileus)
    *   Infection
    *   Altered mental status
    *   Essential fatty acid deficiency

<a id='40961b08-4009-444c-ab44-94ea8264379a'></a>

NASPGHAN
FOUNDATION

<a id='29dc8a90-35f0-4990-947b-c0dfc81dadf8'></a>

Brusilow SW, et al. NEJM 1984;310:1630-4.
Haberle J, et al. Orphanet J Rare Dis. 2012;7:32.

<a id='7f48dab8-bc6b-4eca-8174-f3dd3488605e'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line beneath the text.::>

<a id='1a7ed061-08a8-4819-a5d2-5aecb69912c7'></a>

# Inborn Errors of Metabolism: Phenylketonuria (PKU)

*   Hypercatabolism occurs during stress
    *   Parallels the extent of infection/injury
*   Goal is prevention of prolonged phenylalanine (PHE) elevation
*   Interventions to depress catabolic response
    *   PN as bridge to enteral nutrition
    *   PHE-free parenteral amino-acid solution with some standard parenteral amino acids
        *   Not commercially available
        *   Needs to be made by a compounding pharmacy

<a id='12643533-e785-491d-822d-b19f218b2228'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='afa5711c-010d-48e1-a6de-5182d4b04212'></a>

Acosta PB. (2010) Nutrition Management of Patients with Inherited Metabolic Disorders. Boston.
Jones and Bartlett. 119-174.

<a id='0ac2d046-2e8d-4bea-b7d2-8a7c3b31bac8'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='ee000e20-801b-43fe-9260-a184d6c07760'></a>

# Inborn Errors of Metabolism: Mitochondrial Disorders

* Avoid exposure to PN if possible
* High-glucose diet is a metabolic challenge for impaired oxidative phosphorylation
  * Glucose oxidation is largely aerobic in the liver
* High lipid/low carbohydrate diet recommended in Complex I deficiency
* Carnitine supplementation is recommended in patients with secondary carnitine deficiency
  * Dose of carnitine needed is higher than nutritional doses
  * Carnitine to be administered separately from PN to ensure adequate provision

<a id='d31bc889-85dd-47f7-ab55-873f0638dd1d'></a>

<::NASPGHAN FOUNDATION : figure::>

<a id='d3c705e9-792e-4b83-9ae0-55b8e1aa39d0'></a>

Munnich *et al*. The Online Metabolic & Molecular Bases of Inherited Disease. McGraw-Hill Education; 2019.

<a id='3ae9787a-8d55-4faa-a382-5cc9256f41da'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='30a8f363-56dc-44b9-a7bd-d5836cedf4af'></a>

Inborn Errors of Metabolism:
Propionic Acidemia and Methylmalonic Acidemia (MMA)

<a id='0c9b8212-3b29-4711-a653-d4b1609e677f'></a>

Management of acute crisis
* Remove sources of isoleucine (ILE), methionine (MET), threonine (THR), valine (VAL)
* IV glucose and electrolytes: 150 mL/kg;
  glucose infusion rate (GIR): 10 mg/kg/min
  * Treat metabolic acidosis and maintain normal sodium levels
* Add lipids 2-3 g/kg/day to achieve total caloric goal of 120-150 kcal/kg/day (infant)
* Intravenous L-carnitine 100-300 mg/kg/day to help improve clearance

<a id='ede6bdd0-feab-4443-87bf-99531e22a4be'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='d8820bf1-24e1-48d2-af46-f2d8be56a197'></a>

Forny P, et al. J Inherit Metab Dis. 2021;44:566-92.
Prietsch V, et al. J Inheirit Metab Dis. 2002;25:531-46.
Ney D, et al. J Inherit Metab Dis. 1985;8:132-42.

<a id='fe98744d-fdaa-4966-a613-afc577aa3fb3'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, and bold font, set against a rectangular background that transitions from a darker blue at the top to a lighter blue/white at the bottom, with a subtle dark blue curved line underneath the text.::>

<a id='8bfc0071-66da-4b52-9d8b-f2bff3201895'></a>

Kahler SG, et al. J Pediatr. 1989; 115:235-41.

<a id='f77f6f15-add0-47c7-932c-1b4e6ede4527'></a>

Inborn Errors of Metabolism:
Propionic Acidemia and MMA – Cont'd

<a id='297a0cfb-11e7-4268-88bd-6560b567c9d5'></a>

Management of acute crisis

<a id='b9fdae04-48e0-4d52-9620-644953967687'></a>

* Combination PN (and EN) within 24 - 48 hours to prevent ILE, MET, THR and VAL deficiency
  * Initiate protein at 0.5 g/kg/day and increase as tolerated not exceeding prescribed amounts
  * Monitor daily plasma amino acids until stable
* Peripheral PN will not provide sufficient energy for anabolism

<a id='cca6789f-e177-4e16-b227-570422882cb5'></a>

<::transcription of the content
: NASPGHAN FOUNDATION::>

<a id='797acb86-5df1-43fb-b046-1eb0f6888eb3'></a>

Forny P, et al. J Inherit Metab Dis. 2021;44:566-92.
Prietsch V, et al. J Inheirit Metab Dis. 2002;25:531-46.
Ney D, et al. J Inherit Metab Dis. 1985;8:132-42.

<a id='2edebcf5-ef5f-4c28-923e-f9a8b1f9ed5d'></a>

Kahler SG, et al. J Pediatr. 1989; 115:235-41.

<a id='bdd989c4-3cf7-422f-a429-33af34747cf9'></a>

CAPTION ERROR

<a id='c5f082b9-0c46-47c1-ad6f-f07a086c0b58'></a>

Inborn Errors of Metabolism:
Maple Syrup Urine Disease (MSUD)

<a id='3b924796-3ef8-4354-913a-110fb1962960'></a>

- Comatose or Neurologically compromised patients
  - Goal calories
    Infants: 120 - 140 kcal/kg/day
    Children: 80 - 100 kcal/kg/day
    Adults: 40 - 45 kcal/kg/day

<a id='4cdc252d-a932-4610-9ab6-53a5f5aa883e'></a>

* Add insulin to treat hyperglycemia (need anabolic GIR)

<a id='ef80a237-ecda-4d68-9081-4fab25b6f994'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='aaa83e3d-ba9b-40fd-8f3f-2b2a0fc7555e'></a>

Heldt K, et al. Mol Genet Metab. 2005;84:313-6. Holmes Morton D, et al. Pediatrics 2002:109:999-1008.
Elsas et al. Inherited metabolic disease in Modern Health in Nutrition and Disease. Philadelphia. Lippincott
Williams & Wilkins. 10th Ed. 2006.
www.childrenshospital.org/newenglandconsortium/NBS/MSUD.html.

<a id='0566de36-bf81-4dc0-92d7-64dd3999907b'></a>

CAPTION ERROR

<a id='ac311503-2229-43e9-a696-c639811db7ab'></a>

# Inborn Errors of Metabolism: MSUD – Cont'd
* Use branch chain amino acid (BCAA)-free solution and monitor plasma amino acids
  * Neonates: give 2.5 - 3 g/kg/day protein
  * Plasma ILE/VAL decrease more rapidly then, LEU
  * Add ILE/VAL supplement to PN at lower limits of recommended intake
  * Add LEU when plasma LEU reaches 200µmol/L
  * Not commercially available, needs to be made by a compounding pharmacy
* Normalization of all 3 BCAA usually happens in 48 - 72 hours
* When able to tolerate enteral feeds start BCAA-free food

<a id='74a3c5cc-a253-4ad6-b139-e530630df327'></a>

<::NASPGHAN FOUNDATION: figure::>

<a id='83432e0f-ad62-45ad-8cb0-1f7362e0bbe5'></a>

Heldt K, et al. Mol Genet Metab. 2005;84:313-6. Holmes Morton D, et al. Pediatrics 2002:109:999-1008.
Elsas et al. Inherited metabolic disease in Modern Health in Nutrition and Disease. Philadelphia. Lippincott
Williams & Wilkins. 10th Ed. 2006.
www.childrenshospital.org/newenglandconsortium/NBS/MSUD.html.

<a id='2437c6e6-9fec-4943-96b7-362594d9c7ea'></a>

CAPTION ERROR

<a id='6b548c43-65f1-4bb8-bc34-c5ae51171cb5'></a>

Inborn Errors of Metabolism:
Urea Cycle Disorders (UCDs)

* Provide abundant calories with high glucose and lipids to minimize catabolism
* Reduce nitrogen load
  * Restrict nitrogen intake
  * Activate alternate pathways for nitrogen excretion
* Arginine supplementation needed
  * Available as a separate IV infusion for this purpose
* Monitor closely for catabolic stressors and risk factors for hyperammonemia
  * Birth
  * Illness
  * Excess protein intake
  * Surgery

<a id='0f3c7710-65c3-4acc-a377-cd1a391821b1'></a>

<::NASPGHAN FOUNDATION : figure::>

<a id='e85f3202-2f91-4dba-9f40-89c830f0cb7c'></a>

Brausilow SW, et al. NEJM 1984;310:1630-4.
Häberle J, et al. Orphanet J Rare Dis. 2012;7:32.

<a id='e571972f-6e2e-4d22-adc5-b956960f8b03'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, and italicized text "NASPGHAN" set against a light blue gradient background, with a dark blue curved line beneath it.:>

<a id='876eaf2e-be5d-494a-8f32-d2ffa1684fc1'></a>

# Inborn Errors of Metabolism: UCDs – Cont'd

* Early consideration of parenteral support, if emesis is present to diminish catabolic sequelae
    * High parenteral energy provision
    * 80 - 100 kcal/kg/day for infants
    * 10% dextrose and ILE with glucose infusion rate of 6 - 8 mg/kg/min and 1 - 2 g/kg/day fat
* For persistent catabolism use 10 - 35% dextrose along with insulin (to stop catabolism of glucose)

<a id='562ffaec-0191-427e-ab2c-9eadffff098d'></a>

NASPGHAN
FOUNDATION

<a id='761a74fc-d489-409b-82f8-20b6b6b8b7ec'></a>

Brausilow SW, et al. NEJM 1984;310:1630-4.
Häberle J, et al. Orphanet J Rare Dis. 2012;7:32.

<a id='b2403a34-b07b-4a77-8b14-0a253dc01000'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, italicized text "NASPGHAN" on a blue gradient background with a curved dark blue line underneath.::>

<a id='97e500bf-240b-46fb-b509-89b1fd7023ea'></a>

# Short Bowel Syndrome / Intestinal Failure

*   Pediatric Intestinal Failure as defined by NASPGHAN 2017 as,
    "The need for PN for > 60 days due to intestinal disease, dysfunction or resection."

<a id='e93084fc-4325-42a3-be39-b38cd318786b'></a>

<::table::>
Diagnosis associated with intestinal failure and short bowel syndrome in infants (N=272)
| Diagnosis | N (%) |
|---|---|
| Necrotizing enterocolitis | 71 (26) |
| Gastroschisis | 44 (16) |
| Intestinal atresia (large/small) | 27 (10) |
| Volvulus | 24 (9) |
| Long segment Hirschsprung's disease | 11 (4) |
| Tufting or microvillus inclusion | 3 (1) |
| Other single diagnoses | 14 (5) |
| Unknown | 1 |
| Multiple single diagnoses | 77 (28) |
<::/table::>

<a id='6c6c817a-049a-40ac-9340-552889a6b553'></a>

• PN is needed to meet energy,
fluid, and nutritional
requirements when enteral
nutrition (EN) is insufficient
or cannot be tolerated

<a id='11fe6cd0-5bcf-4c08-a0d0-dd02408bf49e'></a>

<::NASPGHAN FOUNDATION logo
: figure::>

<a id='f35af122-5a09-40bf-8c45-98d2c0192140'></a>

CAPTION ERROR

<a id='32962e0c-4d00-4cf4-883a-500232ca27e4'></a>

<::logo: NASPGHAN
NASPGHAN
The logo displays the dark blue, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping beneath the text.::>